This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Pancreatic Cancer Researchers & Advocates From The Pancreatic Cancer Action Network To Join Rally For Medical Research

MANHATTAN BEACH, Calif., April 8, 2013 /PRNewswire/ -- Researchers and advocates from the Pancreatic Cancer Action Network will join nearly 200 national organizations today in demonstrating their concern about the impact of sequestration on cancer research during the Rally for Medical Research at 11 AM on the steps of the Carnegie Library in Washington, D.C.


The Pancreatic Cancer Action Network is a sponsor of the Rally for Medical Research which will unite millions of Americans across the country to call on our nation's policymakers to ensure lifesaving medical research funding is a national priority and end the sequestration cuts, which took effect on March 1, 2013.  This unified call to action will raise awareness about the critical need for a sustained investment in the National Institutes of Health (NIH) to improve health, spur more progress, inspire more hope and save more lives.

Sequestration slashed the NIH budget by 5.1 percent or approximately $1.5 billion, including a reduction totaling more than $250 million in cancer research funding in FY 2013 alone.  The fight against cancer will be dealt a major setback by these cuts.  For the nation's deadliest cancers, such as pancreatic cancer, where the need for scientific advances is so great, the effects of sequestration could be extremely detrimental.

"Budget cuts to the National Institutes of Health will have a long-lasting and devastating impact on cancer research and we are deeply concerned about the impact on pancreatic cancer, which currently has a five year survival rate of just six percent," said Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network.  "Pancreatic cancer is anticipated to move from the fourth leading cause of cancer death in the United States to the second leading cause of cancer death by the year 2020, or as early as 2015.  We cannot afford to stall the efforts underway to develop early detection methods and more effective treatment options that will lead to better outcomes for pancreatic cancer patients."

Advocates unable to attend the rally in person are encouraged to call their members of Congress on Monday, April 8 between 9 AM and 5 PM (EDT) to tell them to make lifesaving medical and cancer research funding a national priority. To participate, go to

For more information about the Pancreatic Cancer Action Network, go to, and for more information on the Rally for Medical Research, please visit

Follow us:  Watch us: Tweet us: @PanCAN

About the Pancreatic Cancer Action NetworkThe Pancreatic Cancer Action Network is the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization is leading the way to increase the survival rate for people diagnosed with this devastating disease through a bold initiative — The Vision of Progress: Double the Pancreatic Cancer Survival Rate by 2020. Together, we can know, fight and end pancreatic cancer by intensifying our efforts to heighten awareness, raise funds for comprehensive private research, and advocate for dedicated federal research to advance early diagnostics, better treatments and increase chances of survival.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Julie Fleshman

SOURCE Pancreatic Cancer Action Network

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs